Wockhardt Aims For $12m Annual Savings Through US Restructuring
Plus Serum Vaccines Operation And Diabetes Biosimilars Could Bring Firm Back To Profitability
Executive Summary
Wockhardt expects to save up to $12m through restructuring its US business, eyeing up a potential return to profitability by 2025.